Ravina BarrettMOHAMMED ABDULAZIZ MOHAMMED ALTAMIMI2022-05-292022-05-29https://drepo.sdl.edu.sa/handle/20.500.14154/44592The non-selective NSAID naproxen with/without PPI is the most cost-effective option to treat > 65 years OA patients with low risk of gastrointestinal adverse reactions compared to the selective NSAID celecoxib and tramadol whereas the selective NSAID celecoxib with/without PPI is more cost-effective than the non-selective NSAIDs for patients with high risk of gastrointestinal adverse reactionsen